financetom
Business
financetom
/
Business
/
Microsoft's Astonishing Comeback - Its Stunning 974% Decade Growth and the Promise of More to Come!
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Microsoft's Astonishing Comeback - Its Stunning 974% Decade Growth and the Promise of More to Come!
Apr 2, 2024 12:21 PM

Over the last decade, Microsoft ( MSFT )'s stock has demonstrated substantial growth, rising 974%, highlighting its potential as a stable investment for long-term portfolios.

The stock is currently stabilizing at a $420 support level, suggesting the possibility of another sustained upward trend.

 

The past few months have been strong for Microsoft Corp ( MSFT ) . It has formed an uptrend where the stock climbed by 11%, peaking at 14%. The trend began to unfold in January 2024, when the stock surged past the high of 2023 at $384, signaling a decisive victory for buyers pushing the market upwards.

January also witnessed the stock breaking past the psychological $400 resistance. Looking back at 2023, the stock rose by 57%. However, 2022 tells a contrasting story, as the stock experienced a 28% decline while being trapped inside a period consolidation, ranging between $215 and $349.

Taking a long-term view of Microsoft ( MSFT )'s stock offers an overall perspective on its performance. Its 974% growth over the past decade paints a picture of a stock that's a solid pick for long-term portfolios.

Witnessing a 38% plunge from November 2021 to November 2022, the stock certainly faced its share of challenges. However, bouncing back with an impressive 96% recovery from its lows, Microsoft ( MSFT ) showcased its resilience to overcome setbacks.

The stock is currently holding at a $420 support level. Should this support level hold strong, investors might just be on the cusp of witnessing another strong long-term upward trend.

After the closing bell on Monday, April 1, the stock closed at $424.57, trading up by 0.91%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Fed Governor Cook Sues Trump Over Attempt to Fire Her
Market Chatter: Fed Governor Cook Sues Trump Over Attempt to Fire Her
Aug 28, 2025
09:29 AM EDT, 08/28/2025 (MT Newswires) -- Federal Reserve Governor Lisa Cook filed a lawsuit Thursday in federal court contesting President Donald Trump's attempt to oust her from the Board of Governors over allegations she lied on mortgage applications, Bloomberg reported, citing court records. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to...
BRIEF-SciSparc: AutoMax's Shareholders Approve Merger with SciSparc
BRIEF-SciSparc: AutoMax's Shareholders Approve Merger with SciSparc
Aug 28, 2025
Aug 28 (Reuters) - Scisparc Ltd ( SPRC ): * SCISPARC ( SPRC ): AUTOMAX'S SHAREHOLDERS APPROVE MERGER WITH SCISPARC Source text: Further company coverage: ...
CrowdStrike Stock Is Sliding Today: What's Going On?
CrowdStrike Stock Is Sliding Today: What's Going On?
Aug 28, 2025
CrowdStrike Holdings Inc ( CRWD ) shares are trading lower Thursday after the company reported second-quarter results and issued soft revenue guidance for the third quarter. Multiple analysts lowered price targets following the print. What Happened: Cybersecurity company CrowdStrike ( CRWD ) beat analyst estimates on the top and bottom lines in the second quarter, reporting revenue of $1.17 billion...
Telomir Pharmaceuticals Says In Vitro Data Shows Telomir-1 Has Potential as Epigenetic Therapy
Telomir Pharmaceuticals Says In Vitro Data Shows Telomir-1 Has Potential as Epigenetic Therapy
Aug 28, 2025
09:28 AM EDT, 08/28/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said Thursday that recent in vitro data showed that its lead drug candidate Telomir-1 has the potential to help the human body reawaken its natural defenses against disease and decline. In studies conducted by Eurofins Discovery, the drug was shown to potently inhibit UTX, an enzyme that influences...
Copyright 2023-2026 - www.financetom.com All Rights Reserved